-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
OncoSec Medical (NASDAQ:ONCS) Coverage Initiated at StockNews.com
OncoSec Medical (NASDAQ:ONCS) Coverage Initiated at StockNews.com
Investment analysts at StockNews.com assumed coverage on shares of OncoSec Medical (NASDAQ:ONCS – Get Rating) in a research note issued to investors on Thursday. The firm set a "sell" rating on the biotechnology company's stock.
Separately, BTIG Research cut OncoSec Medical from a "buy" rating to a "neutral" rating in a research report on Monday, November 14th.
Get OncoSec Medical alerts:OncoSec Medical Trading Down 8.0 %
ONCS opened at $1.61 on Thursday. The stock has a market cap of $4.78 million, a PE ratio of -0.08 and a beta of 1.48. The stock's 50 day simple moving average is $8.03 and its 200-day simple moving average is $13.07. OncoSec Medical has a 1 year low of $1.55 and a 1 year high of $31.90.
Institutional Trading of OncoSec Medical
An institutional investor recently raised its position in OncoSec Medical stock. Renaissance Technologies LLC grew its position in shares of OncoSec Medical Incorporated (NASDAQ:ONCS – Get Rating) by 48.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 72,898 shares of the biotechnology company's stock after buying an additional 23,900 shares during the quarter. Renaissance Technologies LLC owned approximately 0.19% of OncoSec Medical worth $54,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 13.22% of the company's stock.About OncoSec Medical
(Get Rating)
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer.
See Also
- Get a free copy of the StockNews.com research report on OncoSec Medical (ONCS)
- Is Enterprise Products Partners Fairly Valued?
- Will WhatsApp Partnership Boost MercadoLibre's Earnings?
- 3 Mid-Caps That Could Double in 2023
- Mullen Automotive Shares Jump After Signing New Partner
- REV Group Leads Specialty Vehicle Manufacturers Higher
Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.
Investment analysts at StockNews.com assumed coverage on shares of OncoSec Medical (NASDAQ:ONCS – Get Rating) in a research note issued to investors on Thursday. The firm set a "sell" rating on the biotechnology company's stock.
斯托克新闻网的投资分析师在周四发布给投资者的一份研究报告中假设了OncoSec Medical(纳斯达克代码：ONCS-GET Rating)的股票。该公司对这家生物技术公司的股票设定了“卖出”评级。
Separately, BTIG Research cut OncoSec Medical from a "buy" rating to a "neutral" rating in a research report on Monday, November 14th.
另外，BTIG Research在11月14日星期一的一份研究报告中将OncoSec Medical的评级从“买入”下调至“中性”。
OncoSec Medical Trading Down 8.0 %
OncoSec医疗降价8.0%
ONCS opened at $1.61 on Thursday. The stock has a market cap of $4.78 million, a PE ratio of -0.08 and a beta of 1.48. The stock's 50 day simple moving average is $8.03 and its 200-day simple moving average is $13.07. OncoSec Medical has a 1 year low of $1.55 and a 1 year high of $31.90.
ONCS周四开盘报1.61美元。该股市值为478万美元，市盈率为-0.08，贝塔系数为1.48。该股的50日简单移动均线切入位为8.03美元，200日简单移动均线切入位为13.07美元。OncoSec Medical的一年低点为1.55美元，一年高位为31.90美元。
Institutional Trading of OncoSec Medical
OncoSec医疗的制度性交易
About OncoSec Medical
关于OncoSec医疗
(Get Rating)
(获取评级)
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer.
OncoSec医疗公司是一家晚期免疫肿瘤学公司，专注于设计、开发和商业化基于DNA的肿瘤内疗法，以刺激和增强用于癌症治疗的抗肿瘤免疫反应。该公司的产品线包括用于治疗晚期黑色素瘤的Keynote-695处于第二阶段试验；用于治疗新冠肺炎的Tavo+SARS-CoV-2刺突糖蛋白处于第一阶段临床试验；以及用于治疗头颈部鳞状细胞癌的Tavo+epacadostat+pembrolizumab正处于第一阶段临床试验。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on OncoSec Medical (ONCS)
- Is Enterprise Products Partners Fairly Valued?
- Will WhatsApp Partnership Boost MercadoLibre's Earnings?
- 3 Mid-Caps That Could Double in 2023
- Mullen Automotive Shares Jump After Signing New Partner
- REV Group Leads Specialty Vehicle Manufacturers Higher
- 免费获取StockNews.com关于OncoSec Medical(ONCS)的研究报告
- 企业产品合作伙伴是否得到公平评价？
- WhatsApp合作伙伴关系是否会提振MercadoLibre的收益？
- 2023年中型股可能翻一番
- 马伦汽车签署新合作伙伴后股价上涨
- REV集团引领专用车制造商走高
Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.
接受OncoSec医学日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对OncoSec Medical和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧